The search for a long-term COVID treatment continues, as a randomized clinical trial found that a two-week course of metformin or ursodeoxycholic acid (UDCA) did not meaningfully improve recovery from symptoms, despite earlier evidence suggesting that metformin may reduce long-term risk when taken during acute infection. The findings underscore the continued lack of proven treatments to ease long-term COVID symptoms. This study has been published in Annals of Internal Medicine.
Please follow and like us:
